Tesamorelin / Ipamorelin blend
A supplier blend pairing tesamorelin, a GHRH analogue, with ipamorelin, a ghrelin receptor agonist.
Regulatory status: Not a medicine as a combination. Tesamorelin alone is an approved drug with a label; this pairing is not, and has not been trialled.
Default vial
12 mg
Default mix
3 mL
Reported range
Varies with the blend ratio
Draw (U-100)
25 u
A GHRH analogue plus a ghrelin-receptor agonist in one vial, each with its own entry. Tesamorelin alone is an approved medicine with a label; this combination is not, and pairing them has not been trialled.
Where these numbers come from
No human dosing trial defines a dose for this compound. The numbers here are the values community calculators pre-fill — reference only. Tesamorelin alone has an approved label, but that label describes tesamorelin by itself — it says nothing about this combination, which has not been trialled.
Reviewed October 2026
What it is
- Two compounds in one vial, each with its own Pep-Tidy entry.
- They act on the pituitary by different routes — tesamorelin mimics GHRH, ipamorelin acts at the ghrelin receptor.
- Tesamorelin has an FDA label for a specific indication, HIV-associated lipodystrophy. That label describes tesamorelin alone.
- The combination is a community protocol, not an approved product.
How it is described to act
- 1
Given as one subcutaneous injection containing both.
- 2
Each behaves as it does alone.
- 3
The rationale is that two different pituitary mechanisms produce a larger growth hormone pulse than either alone; this is plausible pharmacology but has not been tested as a product.
- 4
No outcome has been measured for the combination.
What the research has looked at
What the research covers
- Tesamorelin has real trial data behind its approved indication; ipamorelin has a smaller literature. Both are covered in their own entries.
- No published trial tests this combination, so the approved tesamorelin safety record does not describe it.
Where the approved label stops
- Tesamorelin's label covers a specific population and a specific dose of tesamorelin on its own.
- Adding a second compound that raises growth hormone by another route puts the user outside everything that label establishes.
Strength of evidence: Preclinical evidence only
The combination is untested. One component has an approved label, but that label describes it used alone.
What is published comes from cell and animal studies. Findings in those models frequently do not carry over to people.
Reported cautions and unknowns
- A blend is several compounds at once, so an adverse effect cannot be traced to any one of them. Running components separately first is the only way to know which does what.
- Ratios are set by the supplier, not by any standard, so two vials with the same name can contain quite different amounts.
- The safety of the combination has not been studied. What is known, where anything is known, applies to each compound on its own.
- There are no combined pharmacokinetic or toxicity data for any of these blends, so interaction risk is unquantified.
- The FDA's 2026 compounding-committee briefing on BPC-157 documented adverse-event reports and gaps in impurity characterisation for that single peptide.
- Sterility, identity and concentration of multi-peptide compounded vials vary by supplier; only a current third-party Certificate of Analysis can confirm what a vial actually contains.
References
There are none. A search of the published literature returns no studies of this compound — no human trials, no animal work, no cell studies. Anything claimed about it elsewhere is not drawn from published research on this molecule.
Handling this vial
- Lyophilized vials are generally stored at 2–8 °C and kept out of light; once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after 28 days.
- Mix by aiming water down the vial wall and rolling gently — do not shake — and never re-freeze a reconstituted vial.
- Pep-Tidy cannot verify what is in your vial. Ask your supplier for a current Certificate of Analysis (HPLC/MS).
Tesamorelin / Ipamorelin blend questions people ask
How do you reconstitute Tesamorelin / Ipamorelin blend?
A common starting point for a 12 mg vial of Tesamorelin / Ipamorelin blend is 3 mL of bacteriostatic water, which gives 4 mg per mL. Aim the water down the inside wall of the vial, let it dissolve on its own, and roll gently instead of shaking. Pep-Tidy's reconstitution calculator will recalculate the numbers for any other vial size or water volume you use.
How many units of Tesamorelin / Ipamorelin blend is one dose?
At 4 mg per mL, that works out to about 25 units on a U-100 insulin syringe for a 1000 mcg dose. Change the vial size, water volume, or target dose in the calculator and the syringe reading updates with it. This is arithmetic, not a dosing recommendation.
What dosing schedule is reported for Tesamorelin / Ipamorelin blend?
Published and community sources describe Varies with the blend ratio, subcutaneous, every day, typically run 12 weeks on and 4 weeks off. These figures describe what has been reported, not what anyone should take — talk to a licensed clinician first.
How should Tesamorelin / Ipamorelin blend be stored?
Lyophilized Tesamorelin / Ipamorelin blend vials are generally kept at 2–8 °C and out of light. Once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after about 28 days. Never re-freeze a reconstituted vial and never shake it.
Read this before you act on anything above
Everything on this page is a summary of what other people have published — it is not medical advice, not a recommendation, and not a dosing instruction. Reported dose ranges describe what appears in the literature or in community protocols, not what anyone should take. Talk to a licensed clinician before using any peptide.